Empowering CommunityHealth Workers to Lead the Fight Against Breast, Cervical, and Oral
Cancer in Low-Resource Settings

We are thrilled to announce the launchof RaKSA, an innovative Community Health Worker-led program focused
on the early detection of breast, cervical, and oral cancers. Through
this initiative, UE LifeSciences continues its mission of making
cancer screening accessible, affordable, and effective for
underserved populations.

About the RaKSA Initiative

RaKSA integrates iBreastExam,cervAIcal, and OrCA—UE LifeSciences’ award-winning
technologies—into a seamless workflow. These non-invasive,
painless, and radiation-free tools empower Community Health Workers
(CHWs) to conduct comprehensive screenings in low-resource settings.
The initiative is designed to bridge healthcare disparities by
providing accurate and early detection of cancers that
disproportionately affect women in developing countries.

UE LifeSciences: PioneeringAffordable Early Detection

At UE LifeSciences, we arerevolutionizing women's healthcare through cutting-edge, affordable
innovations. iBreastExam is a handheld, battery-operated device
proven effective in detecting breast lesions in dense breast tissue.
cervAIcal is a mobile colposcope that enhances cervical cancer
screening through real-time imaging, while OrCA is a comprehensive
oral cancer assessment system that digitizes documentation and
facilitates remote diagnostics.

By leveraging these technologies, RaKSAequips CHWs with the ability to detect cancers at earlier stages,
leading to better health outcomes. The initiative is particularly
focused on regions where traditional screening methods are not widely
available or affordable.

Key Benefits of RaKSA:

- Triple Cancer Detection: Simultaneousscreening for breast, cervical, and oral cancers in a single visit.

- Non-Invasive & Painless: Usesproven, radiation-free technologies for a comfortable patient
experience.

- Empowering Local Communities: EnablesCHWs to conduct high-quality screenings in low-resource settings,
improving access to life-saving diagnostics.

Impact and Reach

RaKSA is designed to be a scalablesolution that can be implemented across various healthcare settings,
from primary health centers to community health camps. With this
initiative, UE LifeSciences aims to screen over 100,000 women across
low- and middle-income countries (LMICs) in the next two years. The
initiative will focus on increasing awareness, providing training,
and ensuring that women in vulnerable communities have access to
early cancer detection services.

Cancer is a leading cause of deathamong women, particularly in low-resource settings where access to
timely diagnosis is limited. RaKSA addresses these challenges head-on
by providing tools that are easy to use, affordable, and effective.
The program aligns with UE LifeSciences’ vision of ensuring that no
woman is left behind in the fight against cancer.

AboutUE LifeSciences

UELifeSciences is a fast-growing, award-winning women’s health
innovator. It is a leader in developing equitable and accessible
early detection tools for women’s cancers. UE LifeSciences’
hallmark innovation, iBreastExam is enabling breast cancer early
detection for over 2 million women across 10 countries. The company
is soon to launch CervAIcal, a hand-held mobile colposcope to screen
for cervical abnormalities. The product has already obtained CDSCO
approval in India and the European CE Mark. The company has entered
distribution partnerships with Siemens Healthineers (USA), HLL
Lifecare (India) and others. UE Lifesciences is the winner of several
global accolades including the Global Women’s HealthTech award from
The World Bank. With headquarters in the USA and subsidiaries in
India, Malaysia, Colombia and Chile, UE LifeSciences is a proud
Member of the American Cancer Society (ACS) and the Union for
International Cancer Control (UICC).

Stay tuned for more updates on RaKSAand how we are transforming women’s healthcare around the world.